GCP framework and core principle

Good Clinical Practice (GCP) is the international ethical and scientific quality standard for clinical trials. China's current GCP (2020 revision) is benchmarked to ICH E6(R2), and applies to every drug trial conducted in China — whether sponsored by a domestic or a multinational company.

The core principle of GCP: the rights, safety and well-being of subjects take priority over scientific and social interests.

Legal basis

  • Drug Administration Law, Art. 17–22 — trial principles and approval
  • Measures for the Administration of Drug Registration — IND and tacit-consent system
  • GCP (2020) — core technical standard
  • Ethics Review Measures for Biomedical Research Involving Humans
  • Regulations on the Administration of Human Genetic Resources
  • Personal Information Protection Law (PIPL) — subject data protection

Ethics review and informed consent

Ethics committee review

Before any trial begins, the protocol, informed consent form and investigator's brochure must receive independent review and written approval from the site's ethics committee.

  • Composition: medical and non-medical professionals, a legal expert and members independent of the site, with gender balance.
  • Review focus: scientific and ethical soundness, risk–benefit balance, adequacy of consent procedures, fairness of recruitment, and reasonableness of compensation arrangements.
  • Continuing review: at least annually; trials with serious adverse events or major protocol violations may be suspended or terminated.
  • Multi-centre review: either a single (lead-site) review adopted by other sites, or review by each site.

Informed consent — the first line of subject protection

Informed consent is the most fundamental GCP institution. Every subject must voluntarily sign an informed consent form on a fully-informed basis. It is not a one-time "sign here" formality but a continuous, dynamically updated legal process.

  • Nature of the trial: clearly explained as research, not routine treatment, including purpose, the investigational drug and randomisation.
  • Risks and discomforts: reasonably foreseeable risks and inconveniences.
  • Expected benefits: to the subject and others, or disclosure of the absence of expected benefit.
  • Alternative treatments: and their pros and cons.
  • Compensation and treatment: available for trial-related injury.
  • Voluntary participation: refusal or withdrawal at any time without penalty or loss of benefits.
  • Confidentiality: identity kept confidential, with lawful access for authorities, ethics committees and the sponsor's representatives.

Risk note: the legal precision and completeness of the informed consent form directly affect its evidentiary weight in any dispute. We recommend lawyer involvement in drafting — using plain language (not jargon) to cover every statutory element while protecting sponsor and investigator from "inadequate disclosure" claims.

Human genetic resources (HGR)

HGR management is the most policy-sensitive, legally consequential and most easily overlooked area of trial compliance in China. The Ministry of Science & Technology (MOST) has intensified enforcement, and many trials have been suspended or ordered remedied for HGR violations.

What counts as "human genetic resources"?

  • HGR materials: organs, tissues and cells containing human genome and genetic material.
  • HGR information: data generated from HGR materials, such as genome sequencing, gene expression and proteomics data.

Scenarios requiring approval or filing

  • Collection approval: collecting important pedigrees, region-specific or designated HGR requires MOST approval.
  • Preservation approval: preserving Chinese HGR requires approval.
  • International cooperation approval: collaborative research involving foreign parties and Chinese HGR requires approval.
  • Material export approval: shipping, mailing or carrying HGR materials abroad.
  • Information export filing / security review: providing HGR information to foreign parties requires filing; cases affecting national security need review.
  • International cooperative trial filing: trials at Chinese sites not involving material export may be filed (rather than approved).

Consequences of HGR violations

  • Interviews of the project lead and sponsor by MOST
  • Suspension or termination of the project
  • Revocation of issued HGR approvals
  • Confiscation of unlawfully collected/preserved resources and proceeds; fines of CNY 500,000–5,000,000 (or 5–10× unlawful gains above CNY 1,000,000)
  • Record of serious research-integrity breach
  • Criminal liability under Criminal Law Art. 334-1 in serious cases

Practical advice: any China trial with foreign participation — whether direct or indirect via a CRO or central lab — must be assessed for HGR approval/filing. "Information export" is broad: a CRO storing data on overseas servers, a sponsor HQ remotely accessing China data, or a central lab sending samples abroad all count. Assess HGR before the trial starts to avoid mid-trial suspension.

Data integrity and trial data management

  • Source data: every CRF entry must be supported by source documents.
  • Audit trail: any data change must record who, when and why.
  • Electronic data and signatures: must comply with 21 CFR Part 11 or China's equivalent rules.
  • SAE reporting: serious adverse events must be reported within 24 hours to the sponsor, ethics committee and authority.

Subject injury compensation

The sponsor bears the cost of medical treatment and financial compensation for trial-related injury, including death — a mandatory GCP requirement and the core of trial insurance.

  • Trial insurance: sponsors should insure subjects before the trial starts.
  • No-fault principle: compensation is payable where injury is causally related to the trial, regardless of sponsor or investigator fault, unless clearly caused by the subject's own special constitution and disclosed in the consent form.
  • Burden of proof: the subject need only show a preliminary causal link; the sponsor bears the heavier burden of rebutting it.

How we help

  1. Drafting and review: informed consent forms, clinical trial agreements (CTA), investigator brochures and trial insurance contracts.
  2. Ethics committee support: preparing submissions and responding to legal/ethical questions.
  3. HGR end-to-end management: approval/filing judgement, application preparation and cross-border pathways.
  4. Data compliance review: data management plans and the lawful basis for processing subject data.
  5. Trial dispute handling: assessing, negotiating and litigating subject-compensation claims.
  6. Three-party agreements: negotiating sponsor / CRO / site agreements on liability, IP, data rights and damages.